

INVERNESS MEDICAL INNOVATIONS INC  
Form 8-K/A  
November 20, 2003

**SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 8-K/A**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934**

**DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED) September 30, 2003**

**Inverness Medical Innovations, Inc.**

(Exact Name of Registrant as Specified in Its Charter)

**Delaware**

(State or other jurisdiction of  
incorporation)

**001-16789**

(Commission file number)

**04-3565120**

(IRS Employer Identification  
No.)

**51 Sawyer Road, Suite 200, Waltham, Massachusetts 02453**

(Address of principal executive offices)

Registrant's telephone number, including area code: **(781) 647-3900**

**Not Applicable**

(Former name or former address, if changed since last report)

---

Inverness Medical Innovations, Inc. (the Company) hereby amends its Current Report on Form 8-K, event date September 30, 2003, in order to file the financial statements and pro forma financial information required by Item 7 of Form 8-K.

**ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS**

a) **FINANCIAL STATEMENTS OF BUSINESS ACQUIRED**

Audited statements of net assets sold of the Rapid Diagnostics Product Lines of the Abbott Diagnostics Division and Ross Products Division of Abbott Laboratories as of September 30, 2003 and December 31, 2002 and 2001, and the related statements of net sales in excess of expenses for the nine-month period ended September 30, 2003 and the years ended December 31, 2002 and 2001 are contained in Exhibit 99.3 attached hereto and are incorporated herein by reference.

b) **PRO FORMA FINANCIAL INFORMATION**

Unaudited pro forma condensed combined statements of operations of the Company, for the nine months ended September 30, 2003, and for the year ended December 31, 2002, all giving pro forma effect to the Company's acquisition of the Rapid Diagnostics Product Lines of the Abbott Diagnostics Division and Ross Products Division of Abbott Laboratories, are contained in Exhibit 99.4 attached hereto and are incorporated herein by reference.

The consolidated balance sheet of the Company as of September 30, 2003 presented in the Company's quarterly report on Form 10-Q for the quarterly period ended September 30, 2003 reflects the acquisition of the Rapid Diagnostic Product Lines acquired from Abbott Laboratories as of September 30, 2003.

c) **EXHIBITS**

The following exhibits are filed with this document.

<b>Exhibit Number</b>	<b>Description</b>
*+2.1	Asset Purchase Agreement, as of September 30, 2003, by and among Abbott Laboratories and Inverness Medical Innovations, Inc. and Inverness Medical Switzerland GmbH, Morpheus Acquisition Corp. and Morpheus Acquisition LLC
23.1	Consent of Deloitte & Touche LLP

Edgar Filing: INVERNESS MEDICAL INNOVATIONS INC - Form 8-K/A

- \*99.1 Press Release dated October 1, 2003, titled Inverness Medical Innovations, Inc. Acquires Certain Assets From Abbott Laboratories Rapid Diagnostics Business
- \*99.2 Registration Rights Agreement, as of September 30, 2003, by and among Inverness Medical Innovations, Inc. and Abbott Laboratories
- 99.3 Audited statements of net assets sold of the Rapid Diagnostics Product Lines of the Abbott Diagnostics Division and Ross Products Division of Abbott Laboratories as of September 30, 2003 and December 31, 2002 and 2001, and the related statements of net sales in excess of expenses for the nine-month period ended September 30, 2003 and the years ended December 31, 2002 and 2001
- 99.4 Unaudited pro forma condensed combined statements of operations of the Company, for the nine months ended September 30, 2003, and for the year ended December 31, 2002, all giving pro forma effect to the Company's acquisition of the Rapid Diagnostics Product Lines of the Abbott Diagnostics Division and Ross Products Division of Abbott Laboratories

---

\* Previously filed

+ The Company agrees to furnish supplementally to the Securities and Exchange Commission (the Commission ) a copy of any omitted schedule or exhibit to this agreement upon request by the Commission.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INVERNESS MEDICAL INNOVATIONS, INC.

BY:                   /s/ Christopher J. Lindop  
                          Christopher J. Lindop  
                          Chief Financial Officer

Dated: November 20, 2003

**EXHIBIT INDEX**

<b>Exhibit Number</b>	<b>Description</b>
*+2.1	Asset Purchase Agreement, as of September 30, 2003, by and among Abbott Laboratories and Inverness Medical Innovations, Inc. and Inverness Medical Switzerland GmbH, Morpheus Acquisition Corp. and Morpheus Acquisition LLC.
23.1	Consent of Deloitte & Touche LLP
*99.1	Press Release dated October 1, 2003, titled Inverness Medical Innovations, Inc. Acquires Certain Assets From Abbott Laboratories Rapid Diagnostics Business
*99.2	Registration Rights Agreement, as of September 30, 2003, by and among Inverness Medical Innovations, Inc. and Abbott Laboratories
99.3	Audited statements of net assets sold of the Rapid Diagnostics Product Lines of the Abbott Diagnostics Division and Ross Products Division of Abbott Laboratories as of September 30, 2003 and December 31, 2002 and 2001, and the related statements of net sales in excess of expenses for the nine-month period ended September 30, 2003 and the years ended December 31, 2002 and 2001
99.4	Unaudited pro forma condensed combined statements of operations of the Company, for the nine months ended September 30, 2003, and for the year ended December 31, 2002, all giving pro forma effect to the Company's acquisition of the Rapid Diagnostics Product Lines of the Abbott Diagnostics Division and Ross Products Division of Abbott Laboratories

---

\* Previously filed

+ The Company agrees to furnish supplementally to the Securities and Exchange Commission (the Commission ) a copy of any omitted schedule or exhibit to this agreement upon request by the Commission.